Generic Name:
infliximab
Project Status:
Complete
Therapeutic Area:
Rheumatoid arthritis
Manufacturer:
Celltrion Healthcare Co., Ltd
Call for patient/clinician input open:
Brand Name:
Remsima
Project Line:
Reimbursement Review
Project Number:
SR0659-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
Use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
Use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.